Palatin Technologies (PTN) Non Operating Interest Expenses (2010 - 2026)
Palatin Technologies' (PTN) quarterly Non Operating Interest Expenses came in at $1268.0 in Q1 2026, down 29.36% on a YoY basis from $1795.0 in Q1 2025, and up 154.62% quarter-over-quarter from $498.0 in Q4 2025.
Analysis
Palatin Technologies (PTN) Non Operating Interest Expenses (2010 - 2026) Analysis & Trends
Palatin Technologies (PTN) has reported Non Operating Interest Expenses for 16 consecutive years, with $1268.0 the latest figure, recorded in Q1 2026.
- For the quarter ending Q1 2026, Non Operating Interest Expenses fell 29.36% year-over-year to $1268.0; the trailing twelve-month figure through Mar 2026 stood at $7255.0 (down 37.12% YoY), and the FY2025 full-year result was $15025.0, down 97.84% from the prior year.
- Non Operating Interest Expenses climbed to $1268.0 in Q1 2026 per PTN's latest filing, from $498.0 in the prior quarter.
- Across five years, Non Operating Interest Expenses topped out at $1.1 million in Q4 2022 and bottomed at $498.0 in Q4 2025.
- Historically, Non Operating Interest Expenses has averaged $125194.7 across 5 years, with a median of $3487.0 in 2025.
- The sharpest annual moves came in 2022 and 2024: Non Operating Interest Expenses surged 40136.75% in 2022, then plunged 99.45% in 2024.
- Over 5 years, Non Operating Interest Expenses stood at $1.1 million in 2022, then slumped by 37.54% to $696912.0 in 2023, then slumped by 99.45% to $3803.0 in 2024, then sank by 86.91% to $498.0 in 2025, then surged by 154.62% to $1268.0 in 2026.
- According to Business Quant data, Non Operating Interest Expenses over the past three periods registered $1268.0, $498.0, and $2002.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Interest Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 673.00 Mn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | 247.00 Mn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 11.00 Mn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | -1.00 Mn |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 82.05 Mn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | - |
| 10 | Palatin Technologies | 46.98 Mn | 46.98 Mn | - | 1,268.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | 1,268.00 |
| Dec 31, 2025 | 498.00 |
| Sep 30, 2025 | 2,002.00 |
| Jun 30, 2025 | 3,487.00 |
| Mar 31, 2025 | 1,795.00 |
| Dec 31, 2024 | 3,803.00 |
| Sep 30, 2024 | 5,940.00 |
| Mar 31, 2024 | 1,254.00 |
| Dec 31, 2023 | 696,912.00 |
| Sep 30, 2023 | 10,882.00 |
| Mar 31, 2023 | 3,434.00 |
| Dec 31, 2022 | 1.12 Mn |
| Sep 30, 2022 | 9,602.00 |
| Jun 30, 2022 | 18,259.00 |
| Mar 31, 2022 | 3,019.00 |
| Dec 31, 2021 | 2,773.00 |
| Sep 30, 2021 | 5,631.00 |
| Jun 30, 2021 | 14,080.00 |
| Dec 31, 2020 | 1,871.00 |
| Sep 30, 2020 | 7,489.00 |